Gaps in Prenatal Hepatitis B Screening and Management of HBsAg Positive Pregnant Persons in the U.S., 2015–2020
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

Gaps in Prenatal Hepatitis B Screening and Management of HBsAg Positive Pregnant Persons in the U.S., 2015–2020



Public Access Version Available on: July 01, 2024, 12:00 AM
Please check back on the date listed above.
English

Details:

  • Alternative Title:
    Am J Prev Med
  • Personal Author:
  • Description:
    Background:

    The Advisory Committee for Immunization Practices (ACIP) recommends testing all pregnant women for hepatitis B surface antigen (HBsAg) and testing HBsAg–positive pregnant women for hepatitis B virus deoxyribonucleic acid (HBV DNA). HBsAg–positive pregnant persons are recommended by the American Association for the Study of Liver Diseases to receive regular monitoring, including alanine transaminase (ALT) and HBV DNA and antiviral therapy for active hepatitis and to prevent perinatal HBV transmission if HBV DNA level is >200,000 IU/mL.

    Methods:

    Using Optum Clinformatics Data Mart Database claims data, pregnant women who received HBsAg testing and HBsAg–positive pregnant persons who received HBV DNA and alt testing and antiviral therapy during pregnancy and after delivery during January 1, 2015–December 31, 2020 were analyzed.

    Results:

    Among 506,794 pregnancies, 14.6% did not receive HBsAg testing. Pregnant women more likely to receive testing for HBsAg (p<0.01) were persons aged ≥20 years, were Asian, had >1 child, or received education beyond high school. Among the 0.28% (1,437) pregnant women who tested positive for hepatitis B surface antigen, 46% were Asian. The proportion of HBsAg–positive pregnant women who received HBV DNA testing during pregnancy and in the 12 months after delivery was 44.3% and 28.6%, respectively; the proportion that received hepatitis B e antigen was 31.6% and 12.7%, respectively; the proportion that received ALT testing was 67.4% and 47%, respectively; and the proportion that received HBV antiviral therapy was 7% and 6.2%, respectively.

    Conclusions:

    This study suggests that as many as half a million (~14%) pregnant persons who gave birth each year were not tested for HBsAg to prevent perinatal transmission. More than 50% of HBsAg–positive persons did not receive the recommended HBV–directed monitoring tests during pregnancy and after delivery.

  • Subjects:
  • Source:
  • Pubmed ID:
    36906494
  • Pubmed Central ID:
    PMC10994214
  • Document Type:
  • Funding:
  • Collection(s):
  • Main Document Checksum:
  • File Type:
  • Supporting Files:
    No Additional Files
More +

You May Also Like

Checkout today's featured content at stacks.cdc.gov